Business

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

Newly Released Report Details Company’s Progress and Contributions Toward Good Health and Well-Being as a Leading Provider of Affordable Medicines

articleAmneal Pharmaceuticals, Inc.June 15, 20234/company/amneal-pharmaceuticals-inc/news/amneal-releases-2022-environmental-social-and-governance-report-mapped-to-the-united-nations-sustainable-development-goals
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

About this update from Amneal Pharmaceuticals, Inc.

[{"type":"text","content":"\nNewly Released Report Details Company’s Progress and Contributions Toward Good Health and Well-Being as a Leading Provider of Affordable Medicines\n\n\n BRIDGEWATER, N.J.--(BUSINESS WIRE)--\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its third annual (2022) Environmental, Social and Governance (ESG) Report. This 2022 report provides a look at our progress across our ESG focus areas, including updates to our people data and sustainability programs.\n\n\nNew this year, the report is mapped to the United Nations Sustainable Development Goals (UN SDGs) and highlights our contributions in support of Goal 3: Good Health and Well-Being. With a primary focus on addressing critical health needs via innovative and affordable medicines, Amneal is responsibly living its purpose of making healthy possible for patients, communities, and the planet.\n\n\n“Since our founding in 2002, Amneal has always been a purpose-driven company deeply focused on patients. As we diversify and expand our business, we are not only elevating the value we deliver for mankind, but we’re also elevating our commitment to ESG. Our long-term sustainability roadmap is focused on expanding affordable access to essential medicines through our vast product portfolios in complex generics, injectables, specialty and biosimilars,” said Chirag Patel, Co-CEO and Co-Founder.\n\n\n“To truly make healthy possible, we believe that we must also support a healthy planet, so we are strengthening our rigor in environmental responsibility by tracking our global carbon footprint. We are pleased with the incremental improvements we are making across our operations each year and will continue taking action to ensure we’re responsibly executing our purpose,” said Chintu Patel, Co-CEO and Co-Founder.\n\n\nKey 2022 ESG Achievements\n\n\n- Affordability and Accessibility: Saving patients over $10 billion* in the U.S with our generic and biosimilars medicines. Hosting our first-ever global employee volunteering event focused on health and hygiene kit-making and celebrating our 10-year partnership (20+ million doses of Amneal medicine donated to date) providing medicines to underserved and uninsured patients with Dispensary of Hope.\n\n\n- Environmental Stewardship: Creating and convening a Global Environmental Working Group (EWG) to a...

More updates from Amneal Pharmaceuticals, Inc.